MedXY – Page 2 – Medxy AI

Pre-ICU Balanced Crystalloids Reduce Mortality in Sepsis: Insights from a Large Multicenter Cohort Study

By MedXY 09/23/2026

A large multicenter study shows that balanced crystalloids administered before ICU admission in sepsis patients reduce 30-day mortality compared to saline, supporting early fluid choice's impact on sepsis outcomes.

news Ophthalmology Pediatrics

Rising Incidence and Clinical Complexity of Non-Infectious Pediatric Uveitis in the US: Insights from a Decade of TriNetX Data

By MedXY 09/23/2026

This study analyzes the rising incidence and prevalence of non-infectious pediatric uveitis in the United States, detailing demographic distributions, ocular complications, systemic associations, and treatment patterns from 2016 to 2025 using the TriNetX database.

Clinical Updates news Oncology Ophthalmology

Centralized Multidisciplinary Retinoblastoma Care: Closing Outcome Gaps in Resource-Limited Settings with Telemedicine and Advanced Globe Salvage

By MedXY 09/23/2026

Centralized multidisciplinary retinoblastoma care incorporating telemedicine and international partnership at KHCC improved survival and globe salvage rates to levels comparable with high-income countries, demonstrating a scalable model for reducing global disparities over two decades.

news Oncology Otorhinolaryngology

Lymphovascular Invasion as an Independent Prognostic Marker in Laryngeal Squamous Cell Carcinoma: Insights from a National Cohort Study

By MedXY 09/23/2026

Lymphovascular invasion independently predicts worse overall survival in surgically treated laryngeal squamous cell carcinoma, influencing postoperative risk stratification and adjuvant therapy decisions.

news OB/GYN & Women’s Health

Proteinuria as a Prognostic Marker for Pregnancy Outcomes in Preterm Pre-Eclampsia During Expectant Management

By MedXY 09/23/2026

Proteinuria levels in women with preterm pre-eclampsia correlate strongly with pregnancy latency and maternal adverse outcomes but not perinatal outcomes, providing useful prognostic information comparable to angiogenic biomarkers.

Clinical Updates news OB/GYN & Women's Health Oncology

Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis

By MedXY 09/23/2026

This review synthesizes evidence on the cost-effectiveness of standalone salpingectomy for ovarian cancer prevention, highlighting its benefits primarily in women at moderately elevated risk, especially between ages 45-50, supporting tailored prevention strategies.

Clinical Updates Family Medicine & Nutrition news

Whole-Grain Consumption and Cardiometabolic Risk: Evidence from Meta-Analyses of Randomized Controlled Trials

By MedXY 09/23/2026

Higher whole-grain intake consistently improves multiple cardiometabolic risk factors, with optimal benefits at 60–100 g/day. Evidence highlights reductions in adiposity, blood lipids, inflammation, glucose, and blood pressure, supporting whole grains as a key dietary strategy for cardiometabolic health.

Cardiology Neurology news

Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial Infarction

By MedXY 09/23/2026

This study evaluates risk factors for intracranial haemorrhage after tenecteplase fibrinolysis in STEMI patients, developing a prediction model highlighting age, blood pressure, sex, weight, and dose interactions as key determinants.

Clinical Updates news

Emergency Medical Services Equipment Use in the Emergency Department and Its Impact on Time to Care in Out-of-Hospital Cardiac Arrest Patients

By MedXY 09/23/2026

Use of EMS equipment in the ED is associated with shorter time to rhythm analysis and defibrillation for OHCA patients, potentially improving early resuscitation outcomes.

news Oncology

Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma

By MedXY 09/22/2026

This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.

Neurology news Radiology

Temporal Dynamics and Morphological Predictors of Stroke Recurrence After Craniocervical Artery Dissection

By MedXY 09/22/2026

This study delineates how vascular imaging morphologies, notably the double lumen sign, predict time-specific recurrence risk after craniocervical artery dissection, highlighting the hyperacute phase as critical for secondary prevention.

Cardiology Diabetes & Endocrinology news

Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management

By MedXY 09/22/2026

This study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing's syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.

Cardiology news

Gene Editing Therapy in Cardiovascular Disease: Key Takeaways from the 2026 ACC Scientific Statement

By MedXY 09/22/2026

A clinician-focused summary of the 2026 ACC Scientific Statement on gene editing for cardiovascular disease, highlighting indications, recommendations, safety monitoring, ethical issues, and practical steps for integrating these therapies into practice.

Internal Medicine news Public Health

Overcoming Barriers to Medical-Legal Partnerships for Veterans Experiencing Intimate Partner Violence: Insights from the VA

By MedXY 09/22/2026

This qualitative study explores barriers and facilitators to implementing medical-legal partnerships (MLPs) for veterans experiencing intimate partner violence (IPV) within the Veterans Health Administration, highlighting critical organizational, knowledge, and systemic factors.

Clinical Updates news Rheumatology

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

By MedXY 09/22/2026

Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.

Hematology-Oncology news

Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort

By MedXY 09/22/2026

A large Spanish study reveals the shifting landscape of GVHD prophylaxis in alloHSCT, highlighting widespread post-transplant cyclophosphamide use and its impact on acute and chronic GVHD incidence and survival outcomes.

Hematology-Oncology news Oncology

Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern

By MedXY 09/22/2026

T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy's benefits.

Hematology-Oncology news

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma

By MedXY 09/22/2026

Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.

Hematology-Oncology news Pathology & Lab Medicine

Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF)

By MedXY 09/22/2026

This study clinically validates an AI-based quantitative tool, CIF, for bone marrow fibrosis assessment, demonstrating improved reproducibility and accuracy over manual grading without increasing assessment time.

Hematology-Oncology news Pediatrics

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia

By MedXY 09/22/2026

This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival and reduces leukemic burden.